Cooley M&A

JANUARY 23, 2024

Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Additional major acquisitions of 2023 included Pfizer’s acquisition of Seagen for $43 billion and Merck’s acquisition of Prometheus for $10.8

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Growth Business

SEPTEMBER 13, 2023

Investment range: £50,000 – £3m Sectors: fintech, insurtech, regtech, digital health and medical technology, artificial intelligence and machine learning, consumer services, digital media, semiconductors and displays, cybersecurity, enterprise software, autonomous systems and human computer interfaces, novel materials and quantum technology.

Capital 52

Capital Business Funds Investment 52

Cooley M&A

JANUARY 20, 2022

In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. billion strategic combination of One Medical and Iora Health – used all stock. [9] time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Faced with depressed venture funding activity (which for digital health declined nearly 50% from 2021 ), an uncertain IPO market and pressure to provide liquidity to investors, M&A offered digital health startups a solution to deliver liquidity, streamline costs and bridge funding gaps as they continue to develop their products.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

FEBRUARY 11, 2025

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. McKesson is primarily a distributor, meaning that it sells pharmaceuticals, medical supplies, and other medical devices and services to healthcare providers.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. Of course, the targets leverage in the M&A track of a dual-track process inherently increases when the IPO track is a viable strategy. Similarly, Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Mergers and Inquisitions

MARCH 5, 2025

their Enterprise Values are not worth much for a long time): Hedge funds focusing on public biotech companies step into this process after the IPO part, which means they can bet on extreme value inflections based on binary outcomes. If you have an advanced medical or academic background (e.g., or Ph.D.),

Funds 64

Funds Healthcare Mergers and Acquisitions Valuation 64

Razorpay

MARCH 5, 2025

This system works similarly to ASBA in IPOs , where funds stay in the investors account until shares are allotted. Underwriting Process InsureLife begins its underwriting process, reviewing Anils application, documents, and medical reports (if required). This process may take up to 14 days.

Insurance 52

Insurance Underwriting Accountant Funds 52